

**Original Article**

*International Journal of Obesity* (2009) **33**, 326–334; doi:10.1038/ijo.2009.5; published online 17 February 2009

**Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder**

L D Levy<sup>1</sup>, J P Fleming<sup>2</sup> and D Klar<sup>3</sup>

<sup>1</sup>Private clinical practice, Nutritional Disorders Clinic, Toronto, ON, Canada

<sup>2</sup>Private clinical practice, Toronto, ON, Canada

<sup>3</sup>Private clinical practice and Staff Dietitian, Diabetes Clinic, Toronto Western Hospital

Correspondence: Dr LD Levy, Nutritional Disorders Clinic, 34 Berwick Avenue, Toronto, ON, Canada M5P 1H1. E-mail: [dr lancelevy@rogers.com](mailto:dr lancelevy@rogers.com)

Received 26 June 2008; Revised 20 December 2008; Accepted 4 January 2009; Published online 17 February 2009.

**Abstract**

**Objective:** To determine whether attention deficit hyperactivity disorder (ADHD) pharmacological treatment of severely obese subjects with newly diagnosed ADHD would result in sustained weight loss.

**Design:** Longitudinal clinical intervention study of the effects of ADHD medication on weight change over 466 days.

**Subjects:** 78 subjects (6 male, 72 female, mean age 41.3 years, BMI 42.7 kg m<sup>-2</sup>) out of 242 consecutively referred severely obese, weight loss refractory individuals were diagnosed as having ADHD. Sixty-five subjects received treatment and 13 remained as controls.

**Methods:** Standard screening tests identified subjects likely to have ADHD. A diagnosis was made in 78 subjects by semi-structured clinical interview. ADHD subjects were screened for comorbid conditions (binge eating disorder, mood disorder, sleep apnea, chronic pain, gastroesophageal reflux disease). Satisfactory resolution of symptoms of comorbid conditions was achieved prior to the introduction of pharmacotherapy for ADHD. Subjects not accepting, tolerating or remaining on ADHD medication served as controls. Weight was measured at sequential clinic visits after initiation of pharmacotherapy.

**Results:** Comorbid conditions were found to be highly prevalent (sleep apnea 56.4%, binge eating disorder 65.4%, mood disorder 88.4%). After an average of 466 days (s.d.=260) of continuous ADHD pharmacotherapy, weight change in treated subjects was -12.36% of initial weight and in controls +2.78%,  $P<0.001$ . Weight loss in treated subjects was 15.05 kg (10.35%) and weight gain 3.26 kg (7.03%) in controls,  $P<0.001$ .

**Conclusions:** ADHD is a highly prevalent condition in the severely obese population. Treatment of ADHD is associated with significant long-term weight loss in individuals with a lengthy history of weight loss failure. This result is likely because of the positive effects of treatment on self-directedness, persistence and novelty-seeking behaviors. ADHD should be considered as a primary cause of weight loss failure in the obese. Individuals seeking medical or surgical weight loss should be evaluated for ADHD and treated appropriately before intervention. This may improve the outcome for medically managed patients and avoid complications in surgical subjects because of poor compliance with diet and supplement requirements.

**Keywords:** attention deficit hyperactivity disorder, weight loss, refractory obesity, psychostimulants

**MORE ARTICLES LIKE THIS**

These links to content published by NPG are automatically generated

**RESEARCH**

[Childhood Inattention and Dysphoria and Adult Obesity Associated with the Dopamine D4 receptor Gene in Overeating Women with Seasonal Affective Disorder](#)

*Neuropsychopharmacology* Original Article

[Association between symptoms of attention-deficit/hyperactivity disorder and bulimic behaviors in a clinical sample of severely obese adolescents](#)

*International Journal of Obesity* Original Article

[A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs](#)

*Molecular Psychiatry* Original Article

[Dopamine Transporter 3'-UTR VNTR Genotype and ADHD: a Pharmacological-Genetic Study with](#)

**[Methylphenidate](#)**

Neuropsychopharmacology Original Article

[See all 19 matches for Research](#)

*International Journal of Obesity* ISSN 0307-0565 EISSN 1476-5497

[About NPG](#)

[Contact NPG](#)

[RSS web feeds](#)

[Help](#)

[Privacy policy](#)

[Legal notice](#)

[Accessibility statement](#)

[Nature News](#)

[Naturejobs](#)

[Nature Asia](#)

[Nature Education](#)

Search:

go

© 2009 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.  
partner of AGORA, HINARI, OARE, INASP, CrossRef and COUNTER